NUVL Nuvalent

Watchlist

77.640
+0.070+0.09%

Close Mar 20 16:00 ET

77.640
0.0000.00%

Post 16:41 ET

5.56BMarket Cap-19.76P/E (TTM)

About Nuvalent Company

Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.

Company Profile

SymbolNUVL

Company NameNuvalent

Listing DateJul 29, 2021

Issue Price17.00

Founded2017

CEODr. James R. Porter, PhD

MarketNASDAQ

Employees142

Fiscal Year Ends12-31

AddressOne Broadway,14th floor

CityCambridge

ProvinceMassachusetts

CountryUnited States of America

Zip Code02142

Phone1-857-357-7000

Websitehttp://www.nuvalent.com

Company Executives

Name
Position
Salary

Dr. Matthew Shair, PhD
Director, Scientific Founder and Head Scientific Advisor
688.18K

Dr. James R. Porter, PhD
Director, Chief Executive Officer and President
9.38M

Alexandra Balcom, C.P.A.,M.B.A.
Chief Financial Officer, Principal Accounting Officer and Treasurer
3.54M

Henry E. Pelish
Chief Scientific Officer
--

Dr. Deborah Miller, J.D.,PhD
Chief Legal Officer and Secretary
--

Dr. Christopher D. Turner, M.D.
Chief Medical Officer
3.60M

Darlene Noci, A.C.I.S.
Chief Development Officer
--

Anna Protopapas
Independent Director
523.18K

Grant C. Bogle
Independent Director
--

Dr. Michael L. Meyers, M.D.,PhD
Independent Director
494.36K

Dr. Sapna Srivastava, PhD
Independent Director
503.18K

Dr. Joseph Pearlberg, M.D.,PhD
Independent Director
494.00K

Dr. Emily Drabant Conley, PhD
Independent Director
495.90K

Dr. D. Gary Gilliland, M.D.,PhD
Independent Director
495.68K

Dr. Andrew A. F. Hack, M.D.,PhD
Independent Director
495.68K

Dr. Cameron A. Wheeler, PhD
Independent Director
499.45K

NUVL Nuvalent

About Nuvalent Company

Company Profile

Company Executives

Market Insights